Tamiflu correspondence with the World Health Organization

WHO logo

The WHO correspondence begins with an email from Cochrane Collaboration researcher Tom Jefferson in February 2012. He asks WHO scientists how its review process had led to it including oseltamivir in its March 2011 Essential Medicines List.

Had it asked the manufacturers of neuramindase inhibitors for the unpublished trial data? Also, what had WHO scientists made of Cochrane’s conclusion "that there is no evidence that oseltamivir can limit the spread of influenza." The WHO told Jefferson that it was currently developing a standard guideline on clinical management of influenza virus infection. Secondly, it had commissioned several evidence reviews, including one on oseltamivir that was set to appear soon in a peer reviewed medical journal.

Displaying 1-5 out of 5 published

Automated reply from WHO

Competing interests: None declared

Sylvie Briand, Director

Pandemic and Epidemic Disease Department, WHO

Click to like:

Chris Del Mar requests that WHO answer his concerns regarding Tamiflu's inclusion on the Essential Medicines List

Competing interests: None declared

Chris Del Mar, Professor of primary care research and Coordinating Editor of the Cochrane Acute Respiratory Infections Group

Bond University, Queensland, Australia

Click to like:

Dr Sylbie Briand responds to Chris Del Mar

Competing interests: None declared

Sylvie Briand, Director

Pandemic and Epidemic Disease Department, WHO

Click to like:

Corresepondance to Dr Sylvie Briand, regarding the latest update of the WHO Essential Medicines List.

Competing interests: None declared

Chris Del Mar, Coordinating editor

Neuraminidase inhibitors for influenza, Cochrane review team

Cochrane Acute Respiratory Infections Group, Bond University, Queensland, Australia

Click to like:


Competing interests: None declared

Tom Jefferson, Researcher

Peter Doshi

Cochrane Collaboration, Rome

Click to like:

THIS WEEK'S POLL